Author Affiliation: Department of Public Health, Gres, Amiens, France.
Steinman1 stressed that millions of people were early adopters of rofecoxib (Vioxx; Merck Co) and rosiglitazone (Avandia; GlaxoSmithKline), which were withdrawn or restricted for severe safety concerns. Accordingly, the findings of Schwartz and Woloshin2 are very surprising. They showed evidence that a substantial proportion of the public mistakenly believes that the Food and Drug Administration approves only extremely effective drugs and drugs lacking serious adverse effects.2 This deserves 2 questions.
Braillon A. Experience Is a Gloomy Lantern That Does Not Even Illuminate Its Bearer. Arch Intern Med. 2012;172(3):294. doi:10.1001/archinternmed.2011.760
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: